The evaluation of anti-diphtheria toxoid antibodies after 5 years with the primary Tetanus-Diphtheria vaccine in persons aged 6-25 years in Kon Tum, Vietnam: a follow-up study.
Tuan Van Le, Van Thi Tuyet Nguyen, Quan Hoang Nguyen, Huong Le Thien Tran, Son Dinh Tran, Chien Chinh Vien
{"title":"The evaluation of anti-diphtheria toxoid antibodies after 5 years with the primary Tetanus-Diphtheria vaccine in persons aged 6-25 years in Kon Tum, Vietnam: a follow-up study.","authors":"Tuan Van Le, Van Thi Tuyet Nguyen, Quan Hoang Nguyen, Huong Le Thien Tran, Son Dinh Tran, Chien Chinh Vien","doi":"10.3855/jidc.19390","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Diphtheria is a serious infectious disease although being vaccine-preventable. 5-year follow-up study aimed to evaluate the persistence of IgG antibodies to diphtheria toxoid after Tetanus-diphtheria primary immunization for persons aged 6-25 years in Kon Tum, Viet Nam.</p><p><strong>Methodology: </strong>Blood samples were obtained from 128 healthy persons aged 6-25 years collected in 2021. Samples were tested for diphtheria toxoid antibodies by commercial Anti-Diphtheria Toxoid IgG Enzyme-Linked Immunosorbent Assay (ELISA).</p><p><strong>Results: </strong>One month after Td primary vaccination, 92.2% of participants were fully protected against diphtheria (> 0.1 IU/mL). GMCs increased from 0.04 to 0.91 IU/mL at one month, which were maintained in nearly 90% of vaccinees at 5 years. Among children aged 6-10 years, 97.3% had full protection at 1 month after primary vaccination, maintained in 94.6% at 5 years. Among adolescents and adults, 81.0% to 98.5% had full protection at 1 month after vaccination, which were maintained from 72.7% to 96.7% at 5 years. Although, the antibodies slightly declined approximately 5 years post-vaccination, but remained several-fold higher than pre-vaccination.</p><p><strong>Conclusions: </strong>Td vaccine provides long-lasting protective antibodies against diphtheria. These data may inform discussion of the need for Td booster vaccinations among high-risk persons.</p>","PeriodicalId":49160,"journal":{"name":"Journal of Infection in Developing Countries","volume":"19 1","pages":"22-27"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection in Developing Countries","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3855/jidc.19390","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Diphtheria is a serious infectious disease although being vaccine-preventable. 5-year follow-up study aimed to evaluate the persistence of IgG antibodies to diphtheria toxoid after Tetanus-diphtheria primary immunization for persons aged 6-25 years in Kon Tum, Viet Nam.
Methodology: Blood samples were obtained from 128 healthy persons aged 6-25 years collected in 2021. Samples were tested for diphtheria toxoid antibodies by commercial Anti-Diphtheria Toxoid IgG Enzyme-Linked Immunosorbent Assay (ELISA).
Results: One month after Td primary vaccination, 92.2% of participants were fully protected against diphtheria (> 0.1 IU/mL). GMCs increased from 0.04 to 0.91 IU/mL at one month, which were maintained in nearly 90% of vaccinees at 5 years. Among children aged 6-10 years, 97.3% had full protection at 1 month after primary vaccination, maintained in 94.6% at 5 years. Among adolescents and adults, 81.0% to 98.5% had full protection at 1 month after vaccination, which were maintained from 72.7% to 96.7% at 5 years. Although, the antibodies slightly declined approximately 5 years post-vaccination, but remained several-fold higher than pre-vaccination.
Conclusions: Td vaccine provides long-lasting protective antibodies against diphtheria. These data may inform discussion of the need for Td booster vaccinations among high-risk persons.
期刊介绍:
The Journal of Infection in Developing Countries (JIDC) is an international journal, intended for the publication of scientific articles from Developing Countries by scientists from Developing Countries.
JIDC is an independent, on-line publication with an international editorial board. JIDC is open access with no cost to view or download articles and reasonable cost for publication of research artcles, making JIDC easily availiable to scientists from resource restricted regions.